Catalog No.
Product Name
Application
Product Information
Citations
-
HCV Nucleoside Inhibitor
PSI-6130(R 1656) is a Hepatitis C Virus Nucleoside Inhibitor.- Amitava Adhikary, .et al. , J Am Chem Soc., 2014, 136(44): 15646-15653 PMID: 25296262
-
HCV replication Inhibitor
Anguizole is a small molecule inhibits HCV replication and alters NS4B's subcellular distribution.- Choi M, .et al. , Virus Genes., 2013, Dec;47(3):395-407 PMID: 23868571
-
Hepatitis C virus NS3/4a protease inhibitor
Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.- Deqiang Kong, .et al. , Nat Commun, 2024, Jun 8;15(1):4894 PMID: 38849338
- Xinyi Wang, .et al. , Nat Chem Biol, 2023, Oct 23 PMID: 37872400
-
HCV NS3/4A protease inhibitor
Danoprevir is a potent inhibitor of the HCV NS3/4A serine protease.- Deqiang Kong, .et al. , Nat Commun, 2024, Jun 8;15(1):4894 PMID: 38849338
- Xinyi Wang, .et al. , Nat Chem Biol, 2023, Oct 23 PMID: 37872400
- Mahim Khan, .et al. , BMC Complement Med Ther, 2022, Apr 2;22(1):98 PMID: 35366855
- Inês GARCEZ PALHA, .et al. , Biol Open, 2018, Nov 7 PMID: 30404898
- Hui Shen, .et al. , PLoS One., 2013, 8(12): e82299 PMID: 24358168
-
HCV Polymerase Inhibitor
VCH-759 is a non-nucleoside inhibitor of HCV RNA-dependent polymerase with sub-micromolar IC50 values versus genotype 1a/1b replicons.- Hassan GS, .et al. , Eur J Med Chem, 2019, Oct 1;184:111747 PMID: 31604164
-
HCV NS3 protease Inhibitor
Ciluprevir is a specific and potent peptidomimetic inhibitor of the HCV NS3 protease.- Mahim Khan, .et al. , BMC Complement Med Ther, 2022, Apr 2;22(1):98 PMID: 35366855
-
HCV NS3-4A protease inhibitor
Telaprevir (VX-950) is known as protease inhibitors that inhibits the hepatitis C virus NS3.4A serine protease.- Mahim Khan, .et al. , BMC Complement Med Ther, 2022, Apr 2;22(1):98 PMID: 35366855
- Adita Ayu Permanasari, .et al. , BMC Complement Med Ther, 2021, Oct 12;21(1):260 PMID: 34641875
- Che C Colpitts, .et al. , eLife, 2020, 9: e52237 PMID: 32539931
- TS Wahyuni, .et al. , Southeast Asian J Trop Med public health, 2020, 51(1)
- Stefan Bittmann, .et al. , J Regen Biol Med, 2020, 2(2):1-3
- Wahyuni TS, .et al. , J Basic Clin Physiol Pharmacol, 2019, Dec 14 PMID: 31837259
- Jacobs CL, .et al. , Nat Methods, 2018, Jul;15(7):523-526 PMID: 29967496
- Apriyanto DR, .et al. , Jpn J Infect Dis, 2016, May 20;69(3):213-20 PMID: 26255732
- Mizuki Yamamoto, .et al. , Antimicrob Agents Chemother, 2016, Nov; 60(11): 6532-6539 PMID: 27550352
-
NS3 protease inhibitor
Asunaprevir is an inhibitor of the viral enzyme serine protease NS3.- Mahim Khan, .et al. , BMC Complement Med Ther, 2022, Apr 2;22(1):98 PMID: 35366855
- Miyayama Y, .et al. , Microbiol Immunol, 2019, Dec 19 PMID: 31854467
- Kato N, .et al. , Arch Virol, 2019, Dec 12 PMID: 31832864
- Fay EJ, .et al. , J Virol, 2018, Fay EJ PMID: 30282710
- Bennie Lemmens, .et al. , Mol Cell, 2018, Jul 5; 71(1): 117-128.e3 PMID: 30008317
- Ueda Y, .et al. , Virus Res, 2017, May 2;235:37-48 PMID: 28322919
- Furihata T, .et al. , Int J Antimicrob Agents, 2015, Oct;46(4):381-8 PMID: 26163159
- Tomomi Furihata, .et al. , Antimicrob Agents Chemother, 2014, 58(8): 4555-4564 PMID: 24867984
-
HCV Nucleotide Inhibitor
PSI-7977 is a phosphoramidate prodrug of PSI-7851, a nucleoside analog that, when phosphorylated, inhibits the RNA-dependent RNA polymerase of hepatitis C virus (EC50 = 92 nM).- Miyayama Y, .et al. , Microbiol Immunol, 2019, Dec 19 PMID: 31854467
-
NS5A inhibitor
Ledipasvir is an inhibitor of the hepatitis C virus HCV NS5A protein- Miyayama Y, .et al. , Microbiol Immunol, 2019, Dec 19 PMID: 31854467
- Sayuri Nitta, .et al. , Scientific Reports, 2019, 9: 5722 PMID: 30952914
- Sayuri Nitta, .et al. , Sci Rep, 2016, 6: 34652 PMID: 27703205
-
NS5A inhibitor
BMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.- Shirasaki T, .et al. , Hepatology., 2014, 60(5):1519-30 PMID: 24962339
-
HCV NS5A inhibitor
BMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.- TS Wahyuni, .et al. , Southeast Asian J Trop Med public health, 2020, 51(1)
- Miyayama Y, .et al. , Microbiol Immunol, 2019, Dec 19 PMID: 31854467
- Sato K, .et al. , Hepatol Res, 2018, Feb;48(3):E347-E353 PMID: 28834004
-
HCV Protease Inhibitor
Boceprevir is a protease inhibitor used as a treatment for hepatitis C genotype 1.- Ueda Y, .et al. , Virus Res, 2017, May 2;235:37-48 PMID: 28322919
- Shirasaki T, .et al. , Hepatology., 2014, 60(5):1519-30 PMID: 24962339
-
HCV Protease inhibitor
VX-222 is a small molecule non-nucleoside inhibitor of HCV NS5B polymerase that is being investigated for the treatment of hepatitis C virus infection.- Wataru Ito, .et al. , Antivir Chem Chemother, 2015, Dec; 24(5-6): 148-154 PMID: 27503576
- Hui Shen, .et al. , PLoS One., 2013, 8(12): e82299 PMID: 24358168
-
HCV Protease Inhibitor
MK-2748 is a potent inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It demonstrates broad-spectrum antiviral activity across all genotypes (gt1a-gt6) with nanomolar potency (IC₅₀ < 0.115 nM), including strong efficacy against drug-resistant mutant strains such as gt1b R155K (IC₅₀ = 0.032 nM) and D168Y (IC₅₀ = 0.057 nM). MK-2748 is valuable for research on HCV infection and contributes to the understanding of antiviral mechanisms and treatment strategies. -
HCV Protease Inhibitor
AL-611 is an inhibitor of the Hepatitis C virus (HCV) NS5B polymerase, demonstrating potent activity with an EC50 value of 5 nM. This compound plays a critical role in antiviral research, particularly in the development of therapeutic strategies against HCV infections. Its effectiveness in inhibiting HCV replication makes it a valuable tool for studies focused on viral RNA synthesis and enzyme interactions. -
HCV Protease Inhibitor
GSK2818713 is a selective Hepatitis C virus (HCV) protease inhibitor that disrupts the replication complex associated with the NS5A protein. This compound exhibits potent anti-HCV activity, making it a valuable tool for studying the replication and life cycle of the virus. GSK2818713 is applicable in research focused on developing therapeutic strategies against Hepatitis C. -
HCV Protease Inhibitor
BI-1230 is a potent inhibitor of the HCV NS3 protease, exhibiting nanomolar activity in blocking viral replication. It demonstrates high selectivity against other serine and cysteine proteases, making it a valuable tool for studying hepatitis C virus infection mechanisms. Additionally, BI-1230 shows favorable pharmacokinetic properties, supporting its potential use in drug development and research applications related to antiviral therapy. -
HCV Protease Inhibitor
MK-6169 is a potent hepatitis C virus (HCV) protease inhibitor that targets the viral NS5A protein. It exhibits broad-spectrum activity against various HCV genotypes, making it a valuable tool for research on antiviral therapies in hepatitis C. This compound is useful for exploring the mechanisms of HCV replication and potential treatment strategies in pharmaceutical development. -
HCV Protease Inhibitor
Isoeuphorbetin is a dimeric coumarin that acts as a potent inhibitor of HCV protease, demonstrated by an IC50 value of 3.63 µg/mL. This compound has significant potential in antiviral research, particularly in the development of therapeutics targeting hepatitis C virus infection. Its ability to effectively block viral protease activity makes it a valuable tool for studying HCV biology and drug discovery. -
HCV Protease Inhibitor
Ac-D-DGla-LI-Cha-C is a potent inhibitor of the hepatitis C virus (HCV) protease, effectively disrupting viral replication. This peptide is instrumental in studying various biological processes and diseases, including cancer, autoimmune disorders, fibrotic conditions, inflammatory responses, neurodegenerative diseases, infectious diseases, lung and cardiovascular disorders, as well as metabolic diseases. Its targeted action on HCV protease makes it a valuable tool for research in virology and therapeutic development. -
HCV Polymerase Inhibitor
Setrobuvir (ANA-598) is a direct-acting antiviral or DAA, is a non-nucleoside inhibitor of the HCV RNA polymerase -
alpha-glucosidase I inhibitor
Celgosivir is an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. -
Polymerase inhibitor
Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). -
NS3 protease inhibitor
Narlaprevir is a potent, selective, orally bioavailable NS3 protease inhibitor(Ki=6 nM; EC90=40 nM) -
HCV NS5B polymerase inhibitor
Mericitabine (RG 7128; R-7128) is a nucleoside inhibitor of the HCV NS5B polymerase that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication. -
HCV NS3/4A protease inhibitor
Simeprevir is a potent inhibitor of HCV NS3/4A protease (Ki = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM). -
NS5B polymerase inhibitor
Tegobuvir (GS-9190 is a non-nucleoside NS5B polymerase inhibitor. -
HCV NS3/4A protease inhibitor
Vaniprevir is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease. -
HCV NS3/4A protease inhibitor
Voxilaprevir (GS-9857) is a fluorinated macrocyclic hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor with potent in vitro antiviral activity against genotypes 1-6 HCV and broad coverage of NS3/4A protease polymorphisms. GS-9857 improves coverage against commonly encountered NS3 resistance-associated variants (RAVs). -
HCV NS5B polymerase inhibitor
Deleobuvir (BI207127) was a non-nucleoside hepatitis C virus NS5B polymerase inhibitor for the treatment of hepatitis C
-
HCV NS5A inhibitor
MK 8742, also known as Elbasvir, is a HCV NS5A inhibitor, which is an all-oral, interferon-free regimen for the treatment of HCV infection. -
HCV NS5A inhibitor
Velpatasvir, also known as GS-5816, is a potent and selective Hepatitis C virus NS5A inhibitor. -
HCV NS5A inhibitor
Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a. -
HCV NS3/4A inhibitor
Paritaprevir (ABT-450) is a potent non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. -
HCV NS5A inhibitor
Ledipasvir acetone is the active pharmaceutical ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon. -
HCV NS3/4A protease inhibitor
Glecaprevir, also known as ABT-493 and A-1282576, is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM. -
HCV RNA replication inhibitor
Sofosbuvir impurity C is the less active impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
